Effects of an anti-viral interferon booster, RIG-I agonist (RIG-101), on influenza infection in vitro and in vivo - Vienna 2024

Acute respiratory infection: research at the cutting edge

Chair(s): Gernot G.U. Rohde, Tommaso Morelli

Session type: Oral presentation

Effects of an anti-viral interferon booster, RIG-I agonist (RIG-101), on influenza infection in vitro and in vivo

Hugo Ombredane

EVENTS HOME

Previous presentation

Next presentation

Session content

Healthcare worker views on antimicrobial resistance in chronic respiratory disease

Sachin Ananth

Replay

Poster

Abstract

Slides

Determinants of respiratory tract aerosol generation in a diverse clinical population.

George Nava

Replay

Poster

Abstract

Slides

Causal affects of Nasal microbiota on COVID-19 phenotypes: A two-sample bidirectional Mendelian randomization study

Rui Guo

Replay

Poster

Abstract

Slides

Iron metabolism disorder irritates susceptibility to bacterial pneumonia, viral pneumonia, and sepsis

Zhenchao Wu

Replay

Poster

Abstract

Slides

Comparison of RSV, influenza and COVID-19 clinical characteristics in hospitalized infants in ValladolidSpain, 20102022

Alejandro Sanz

Replay

Poster

Abstract

Slides

Pre-clinical development of a novel cross-protective rhinovirus vaccine.

Stephen Shaw

Replay

Poster

Abstract

Slides

Effects of an anti-viral interferon booster, RIG-I agonist (RIG-101), on influenza infection in vitro and in vivo

Hugo Ombredane

Replay

Poster

Abstract

Slides

Efficacy and safety of SR1375 in hospitalized patients with pneumonia combined with underlying disease: a randomized, double-blind, placebo-parallel controlled trial

Rui Xu

Replay

Poster

Abstract

Slides

Discussion and Q&A

CDN Connection Issue

The ERS Congress 2024, Vienna

#{title}